all-(Z)-3-thia-6,9,12,15-octadecatetraenoic acid

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: all-(Z)-3-thia-6,9,12,15-octadecatetraenoic acid
• 英文别名: 3-Thia-6,9,12,15-octadecatetraenoic acid；2-[(3Z,6Z,9Z,12Z)-pentadeca-3,6,9,12-tetraenyl]sulfanylacetic acid
• 化学式: C₁₇H₂₆O₂S
• 分子量: 294.458
• InChiKey: KBTOOHDAHNWJDH-LTKCOYKYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  5.1
• 重原子数：
  20
• 可旋转键数：
  12
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.47
• 拓扑面积：
  62.6
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  全顺式二十碳五烯酸 在 吡啶 、 lithium hydroxide 、 sodium tetrahydroborate 、 甲酸 、 溴 、 碘 、 potassium carbonate 、 potassium hydrogencarbonate 、 过碘酸 、 三苯基膦 、 potassium iodide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 甲醇 、 水 、 乙腈 为溶剂， 反应 69.0h， 生成 all-(Z)-3-thia-6,9,12,15-octadecatetraenoic acid
  参考文献：
  名称：

  一些与二十碳五烯酸和二十二碳六烯酸有关的多不饱和含硫和氧的脂肪酸的合成。

  摘要：

  为了选择性增强二十碳五烯酸（EPA）和二十二碳六烯酸（DHA）的有益生物学作用，已经分别从EPA和DHA开始合成了链中含有硫或氧原子的许多多不饱和脂肪酸。这些酸的氧化降解导致相应的醛全-（Z）-3,6,9,12-十五碳烯醛和全-（Z）-3,6,9,12,15-十八碳烯醛。与DBU的反应分别将这些醛定量地转化为共轭异构体（2E，6Z，9Z，12Z）-十五碳烯醛和（2E，6Z，9Z，12Z，15Z）-十八碳烯醛。通过一系列反应将四种醛转化，所述反应包括还原成醇，卤化并用巯基酯取代成相应的含硫多不饱和脂肪酸酯。

  DOI：

  10.3891/acta.chem.scand.53-0436

文献信息

• Novel lipid compounds
  申请人：Pronova BioPharma Norge AS

  公开号：EP2147910A1

  公开（公告）日：2010-01-27

  The present invention relates to lipid compounds of the general formula (I): wherein R1 is selected from a C10-C22 alkyl, a C10-C22 alkenyl having 1-6 double bonds, and a C10-C22 alkynyl having 1-6 triple bonds;R2 and R3 are the same or different and may be selected from a group of different substituents; Y is selected from suphur, sulfoxide, and sulfone; and X represents a carboxylic acid or a derivative thereof, a carboxylic ester, a carboxylic anhydride or a carboxamide; or a pharmaceutically acceptable salt, complex or solvate thereof. The invention also relates to pharmaceutical compositions and lipid compositions comprising such compounds, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to the cardiovascular, metabolic and inflammatory disease area.

  本发明涉及通式（I）的脂质化合物： 其中R1选自C10-C22烷基，具有1-6个双键的C10-C22烯基，具有1-6个三键的C10-C22炔基； R2和R3相同或不同，可选自不同取代基的一组；Y选自硫、亚砜和砜；X代表羧酸或其衍生物，羧酸酯，羧酸酐或羧酰胺；或其药学上可接受的盐，络合物或溶剂化物。 该发明还涉及包含这种化合物的药物组合物和脂质组合物，以及用作药物或用于治疗，特别是用于治疗与心血管、代谢和炎症相关疾病领域的这种化合物。
• NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT
  申请人：Holmeide Anne Kristin

  公开号：US20110190395A1

  公开（公告）日：2011-08-04

  The present disclosure relates to lipid compounds of general formula (I) wherein R 1 is chosen from a C 10 -C 22 alkyl group, a C 10 -C 22 alkenyl group having 1-6 double bonds, and a C 10 -C 22 alkynyl group having 1-6 triple bonds; R 2 and R 3 are the same or different and may be selected from different substituents; Y is chosen from sulphur, sulfoxide, and sulfone; and X is a carboxylic acid or a derivative thereof, a carboxylic ester, a carboxylic anhydride, or a carboxamide; or a pharmaceutically acceptable salt, complex, or solvate thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising such compounds, and methods of using such compounds such as for treating diseases related to cardiovascular, metabolic, and/or inflammatory diseases.

  本公开涉及通式（I）的脂质化合物，其中R1选择自C10-C22烷基，具有1-6个双键的C10-C22烯基，和具有1-6个三键的C10-C22炔基；R2和R3相同或不同，可以选择不同的取代基；Y选择自硫、亚硫酸和磺酰基；X是羧酸或其衍生物、羧酸酯、羧酸酐或羧酰胺；或其药学上可接受的盐、复合物或溶剂化物。本公开还涉及包含这种化合物的制药组合物和脂质组合物，以及使用这种化合物的方法，例如用于治疗与心血管、代谢和/或炎症相关的疾病。
• SALICYLATE FATTY ACID DERIVATIVES
  申请人：Hovland Ragnar

  公开号：US20130046013A1

  公开（公告）日：2013-02-21

  Fatty acid conjugates of salicylate derivatives and compositions thereof are disclosed. Further disclosed are methods for treating various diseases comprising the administration of an effective amount of at least one compound according to the present disclosure.

  本文公开了水杨酸衍生物的脂肪酸共轭物及其组合物。进一步公开了治疗各种疾病的方法，包括根据本公开的至少一种化合物的有效量进行给药。
• US8759558B2
  申请人：——

  公开号：US8759558B2

  公开（公告）日：2014-06-24
• [EN] NOVEL SULPHUR CONTAINING LIPIDS FOR USE AS FOOD SUPPLEMENT OR AS MEDICAMENT<br/>[FR] NOUVEAUX LIPIDES CONTENANT DU SOUFRE POUR UTILISATION EN TANT QUE SUPPLÉMENT ALIMENTAIRE OU MÉDICAMENT
  申请人：PRONOVA BIOPHARMA NORGE AS

  公开号：WO2010008299A1

  公开（公告）日：2010-01-21

  The present invention relates to lipid compounds of the general formula (I): (I) wherein R1 is selected from a C10-C22 alkyl, a C10-C22 alkenyl having 1-6 double bonds, and a C10-C22 alkynyl having 1-6 triple bonds;R2 and R3 are the same or different and may be selected from a group of different substituents; Y is selected from sulphur, sulfoxide, and sulfone; and X represents a carboxylic acid or a derivative thereof, a carboxylic ester, a carboxylic anhydride or a carboxamide; or a pharmaceutically acceptable salt, complex or solvate thereof. The invention also relates to pharmaceutical compositions and lipid compositions comprising such compounds, and to such compounds for use as medicaments or for use in therapy, in particular for the treatment of diseases related to the cardiovascular, metabolic and inflammatory disease area.